137 related articles for article (PubMed ID: 25770768)
1. Long-Term Administration of Docetaxel Over 70 Cycles for Castration-Resistant Prostate Cancer.
Takahashi M; Kusuhara Y; Mori H; Komori M; Kagawa J; Fukawa T; Yamamoto Y; Yamaguchi K; Fukumori T; Kanayama H
Clin Genitourin Cancer; 2015 Aug; 13(4):e337-e340. PubMed ID: 25770768
[No Abstract] [Full Text] [Related]
2. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
Sonpavde G; Pond GR; Templeton AJ; Fandi A; Tombal B; Rosenthal M; Armstrong AJ; Petrylak DP
Eur Urol; 2016 Jun; 69(6):980-3. PubMed ID: 26497922
[TBL] [Abstract][Full Text] [Related]
3. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Li J; Armstrong AJ
Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
[No Abstract] [Full Text] [Related]
4. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
[TBL] [Abstract][Full Text] [Related]
5. Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer.
Parker SJ; Pond GR; Agarwal N; Alex A; Heilbrun ME; Sonpavde G
Clin Genitourin Cancer; 2017 Feb; 15(1):53-59. PubMed ID: 27338517
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel in castration-resistant prostate cancer: a single-centre experience.
Detti B; Franceschini D; Saieva C; Di Brina L; Baki M; Meattini I; Di Cataldo V; Pasquetti EM; Furfaro I; Mancuso A; Simontacchi G; Livi L
Cancer Invest; 2014 Nov; 32(9):445-50. PubMed ID: 25259606
[TBL] [Abstract][Full Text] [Related]
8. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
[TBL] [Abstract][Full Text] [Related]
9. A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.
van Dodewaard-de Jong JM; de Klerk JMH; Bloemendal HJ; Oprea-Lager DE; Hoekstra OS; van den Berg HP; Los M; Beeker A; Jonker MA; O'Sullivan JM; Verheul HMW; van den Eertwegh AJM
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1319-1327. PubMed ID: 28421240
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.
De Luca R; Costa RP; Tripoli V; Murabito A; Cicero G
Oncology; 2018; 94(3):161-166. PubMed ID: 29241166
[TBL] [Abstract][Full Text] [Related]
11. Correlation between Automated Bone Scan Index Change after Cabazitaxel and Survival among Men with Castration-Resistant Prostate Cancer.
Miyoshi Y; Sakamoto S; Kawahara T; Uemura K; Yokomizo Y; Uemura H
Urol Int; 2019; 103(3):279-284. PubMed ID: 31461725
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.
Yamamoto A; Kato M; Matsui H; Ishida R; Kimura T; Funahashi Y; Sassa N; Matsukawa Y; Kamihira O; Hattori R; Gotoh M; Tsuzuki T
Int J Clin Oncol; 2018 Jun; 23(3):584-590. PubMed ID: 29397469
[TBL] [Abstract][Full Text] [Related]
13. [Recent advances in treatment of patients with castration-resistant prostate cancer after docetaxel failure].
Chen BD; Yu SC; Li GH
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 Jan; 43(1):115-8. PubMed ID: 24616470
[TBL] [Abstract][Full Text] [Related]
14. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
[TBL] [Abstract][Full Text] [Related]
15. Clinical Impact of the Number of Treatment Cycles in First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer.
Kongsted P; Svane IM; Lindberg H; Sengeløv L
Clin Genitourin Cancer; 2017 Apr; 15(2):e281-e287. PubMed ID: 27692811
[TBL] [Abstract][Full Text] [Related]
16. Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer.
Gyawali B; Koomulli-Parambil S; Iddawela M
Crit Rev Oncol Hematol; 2016 Jun; 102():118-24. PubMed ID: 27157868
[TBL] [Abstract][Full Text] [Related]
17. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
Dreicer R
Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
[No Abstract] [Full Text] [Related]
18. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA
J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138
[TBL] [Abstract][Full Text] [Related]
19. [Clinical Study on the Efficacy and Continuous Docetaxel Based Chemotherapy Treatment for Castration-Resistant Prostate Cancer].
Chikazawa I; Inoue S; Nakazawa Y; Nakai D; Morita N; Tanaka T; Motoo Y; Miyazawa K
Hinyokika Kiyo; 2017 Sep; 63(9):351-357. PubMed ID: 28992664
[TBL] [Abstract][Full Text] [Related]
20. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]